The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Parhi, P., Mohanty, C., & Sahoo, S. K. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.06.015 · Cited by 14
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Bangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging
Parveen, S., Misra, R., & Sahoo, S. K. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.05.016 · Cited by 1,436
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Nanotech approaches to drug delivery and imaging
Sahoo, S. K., & Labhasetwar, V. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02903-9 · Cited by 1,203
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., et al. (2002) · Science · doi:10.1126/science.1071420 · Cited by 967
The present and future of nanotechnology in human health care
Sahoo, S. K., Parveen, S., & Panda, J. J. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.11.008 · Cited by 905
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
Maruyama, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.003 · Cited by 601
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Cheng, Y., Zhao, L., Li, Y., & Xu, T. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00097c · Cited by 515
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Crown, J., & O'Leary, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02074-2 · Cited by 352
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice
Kim, J.-H., Kim, Y.-S., Park, K., Lee, S., Nam, H. Y., Min, K. H., Jo, H. G., Park, J. H., Choi, K., Jeong, S. Y., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.014 · Cited by 350
Bawarski, W. E., Chidlowsky, E., Bharali, D. J., & Mousa, S. A. (2008) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.002 · Cited by 337
Nanomaterials for Cancer Therapy and Imaging
Bae, K. H., Chung, H. J., & Park, T. G. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0051-5 · Cited by 313
Cooperative nanomaterial system to sensitize, target, and treat tumors
Park, J.-H., von Maltzahn, G., Xu, M. J., Fogal, V., Kotamraju, V. R., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909565107 · Cited by 307
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy
Yang, X.-Z., Dou, S., Sun, T.-M., Mao, C.-Q., Wang, H.-X., & Wang, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.035 · Cited by 242
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Nanomedicine based approaches for the delivery of siRNA in cancer
Ozpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 218
Yaseen, A. D. B., Kawaguchi, T., & Jankowiak, R. (2009) · International Journal of Nanomanufacturing · doi:10.1504/ijnm.2009.028116 · Cited by 218
Jain, A., Jain, S. K., Ganesh, N., Barve, J., & Beg, A. M. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.03.002 · Cited by 214
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S. K. L., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 213
Zhang, W., Shi, Y., Chen, Y., Yu, S., Hao, J., Luo, J., Sha, X., & Fang, X. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.04.017 · Cited by 180
Duan, J., Zhang, Y., Han, S., Chen, Y., Li, B., Liao, M., Chen, W., Deng, X., Zhao, J., & Huang, B. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.033 · Cited by 175
Zhu, Z., Li, Y., Li, X., Li, R., Jia, Z., Li, R., Guo, W., Wu, W., & Jiang, X. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.002 · Cited by 169
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
Nowotnik, D. P., & Cvitkovic, E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.004 · Cited by 167
Tagami, T., Ernsting, M. J., & Li, S.-D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.009 · Cited by 166
Tagami, T., Ernsting, M. J., & Li, S. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.020 · Cited by 164
Davies, C. D. L., Lundstrøm, L. M., Frengen, J., Eikenes, L., Bruland, Ø. S., Kaalhus, O., Hjelstuen, M. H. B., & Brekken, C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0576 · Cited by 163
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101
Svenson, S., Wolfgang, M., Hwang, J., Ryan, J. L., & Eliasof, S. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.007 · Cited by 153
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)
Danhauser-riedl, S., Hausmann, E., Schick, H.-D., Bender, R., Dietzfelbinger, H., Rastetter, J., & Hanauske, A.-R. (1993) · Investigational New Drugs · doi:10.1007/bf00874153 · Cited by 152
Hamaguchi, T., Doi, T., Nakajima, T. E., Kato, K., Yamada, Y., Shimada, Y., Fuse, N., Ohtsu, A., Matsumoto, S.-I., Takanashi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0387 · Cited by 145
Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy
Lammers, T., Šubr, V., Ulbrich, K., Hennink, W. E., Storm, G., & Kiessling, F. M. (2010) · Nano Today · doi:10.1016/j.nantod.2010.05.001 · Cited by 145
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., & Palmieri, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn661 · Cited by 145
Sabbatini, P. J., Aghajanian, C. A., Dizon, D. S., Anderson, S., Dupont, J., Brown, J. V., Peters, W. A., Jacobs, A. D., Mehdi, A., Rivkin, S. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.043 · Cited by 125
Lammers, T., Peschke, P., Kühnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., & Storm, G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.032 · Cited by 124
Sparano, J. A., Makhson, A. N., Семиглазов, В. Ф., Tjulandin, S., Balashova, O. I., Bondarenko, I., Bogdanova, N. V., Manikhas, G. M., Oliynychenko, G. P., Chatikhine, V. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5013 · Cited by 116
Homsi, J., Simon, G. R., Garrett, C. R., Springett, G. M., Conti, R. C. D., Chiappori, A., Münster, P. N., Burton, M. K., Stromatt, S. C., Allievi, C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2821 · Cited by 103
Lobo, C. F., Lopes, G. D. L., Jr., Baez, O., Castrellon, A. B., Ferrell, A., Higgins, C., Hurley, E., Hurley, J. E., dos Reis, I. M., Richman, S. P., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1002-0 · Cited by 90
Ding, D., Zhu, Z., Liu, Q., Wang, J., Hu, Y., Jiang, X., & Li, R. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.008 · Cited by 84
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Sankhala, K. K., Mita, A. C., Adinin, R., Wood, L. M., Beeram, M., Bullock, S., Yamagata, N., Matsuno, K., Fujisawa, T., & Phan, A. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2535 · Cited by 84
Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use
Gaitanis, A., & Staal, S. P. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-609-2_26 · Cited by 83
Oh, K. S., Song, J. Y., Cho, S. H., Lee, B. S., Kim, S. Y., Kim, K., Jeon, H., Kwon, I. C., & Yuk, S. H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.021 · Cited by 82
Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies
Kohandel, M., Mehran Kardar, A., Milosevic, M., & Sivaloganathan, S. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/13/001 · Cited by 82
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Bolling, C., Graefe, T., Lübbing, C., Jankevičius, F., Uktveris, S., Česas, A., Meyer‐Moldenhauer, W., Starkmann, H., Weigel, M. T., Burk, K., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-8221-6 · Cited by 77
Zamboni, W. C., Ramalingam, S. S., Friedland, D., Edwards, R. P., Stoller, R. G., Strychor, S., Maruca, L. J., Zamboni, B. A., Belani, C. P., & Ramanathan, R. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1405 · Cited by 63
Nanomedicine transforms drug delivery
Shaffer, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03654-8 · Cited by 58
Liechty, W. B., Caldorera‐Moore, M. E., Phillips, M. A., Schoener, C. A., & Peppas, N. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.009 · Cited by 53
Veltkamp, S. A., Witteveen, E. O., Capriati, A., Crea, A., Animati, F., Voogel-Fuchs, M., van den Heuvel, I. J. G. M., Beijnen, J. H., Voest, E. E., & Schellens, J. H. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0438 · Cited by 43
Kim, H. J., Kim, K. H., Yun, J., Kim, S. H., Kim, H. J., Lee, S., Bae, S. B., Kim, C. K., Lee, N. S., Lee, K. T., et al. (2011) · Cancer Research and Treatment · doi:10.4143/crt.2011.43.1.19 · Cited by 15
Bigioni, M., Parlani, M., Bressan, A., Bellarosa, D., Rivoltini, L., Animati, F., Crea, A., Bugianesi, R., Maggi, C. A., Manzini, S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24661 · Cited by 10
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 657
Metadata
- Authors
- Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L.
- Venue
- Clinical and Translational Oncology
- Published
- 2012-02
- Volume
- 14
- Issue
- 2
- Pages
- 83-93
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- OpenAlex
- W2005655958
- Cited by
- 268
- References
- 96
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.